ReviewReumatologia
Glucocorticoid management in rheumatoid arthritis: morning or night low dose?
Review in Reumatologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 44 citations in OpenAlex.
- IgD-Expressing Mature B Cells Exhibit Enhanced Sensitivity to Glucocorticoid-Induced Cell Death.European journal of immunology · 2026Article
- Targeted nanoliposomes for precision rheumatoid arthritis therapy: a review on mechanisms andDrug delivery · 2025Review
- Role of the tendon circadian clock in tendinopathy and implications for therapeutics.International journal of experimental pathology · 2025Review
- Disruption of day-to-night changes in circadian gene expression with chronic tendinopathy.The Journal of physiology · 2024Article
- Central and Peripheral Inflammation: A Common Factor Causing Addictive and Neurological Disorders and Aging-Related Pathologies.International journal of molecular sciences · 2023Review
- Association between levels of serotonin, melatonin, cortisol and the clinical condition of patients with rheumatoid arthritis.Rheumatology international · 2023Article
- The Effective Treatment of Purpurin on Inflammation and Adjuvant-Induced Arthritis.Molecules (Basel, Switzerland) · 2023Article
- Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinibTherapeutic advances in musculoskeletal disease · 2021Article
- Regulatory T cells confer a circadian signature on inflammatory arthritis.Nature communications · 2020Article
- Review
- A General Introduction to Glucocorticoid Biology.Frontiers in immunology · 2019Review
- A new design for a chronological release profile of etodolac from coated bilayer tablets:Journal of advanced research · 2019Article
- Turkish League Against Rheumatism (TLAR) Recommendations for the Pharmacological Management of Rheumatoid Arthritis: 2018 Update Under Guidance of Current Recommendations.Archives of rheumatology · 2018Article
- Unveiling "Musica Universalis" of the Cell: A Brief History of Biological 12-Hour Rhythms.Journal of the Endocrine Society · 2018Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Morning symptoms of rheumatoid arthritis (RA) are linked to circadian increase of night inflammation, supported by inadequate cortisol secretion in active disease. Therefore, exogenous glucocorticoid administration in RA is recommended by EULAR and ACR from the beginning of the diagnosis, since may partially act like a "replacement therapy". In addition, the prevention/treatment of the night up-regulation of the immune/inflammatory reaction has been shown more effective when exogenous glucocorticoid administration is managed with a night-time-release formulation. Despite a considerably higher cost than conventional prednisone (immediate release), chronotherapy with night-time-release prednisone has been recognized a cost-effective option for RA patients not on glucocorticoids who are eligible for therapy with biologic disease-modifying antirheumatic drugs (DMARDs). Interestingly, since different cell populations involved in the inflammatory process are particularly activated during the night (i.e. monocytes, macrophages), other therapeutical approaches used in RA, such as conventional DMARDs and non-steroidal anti-inflammatory drugs (NSAIDs) should follow the same concepts of glucocorticoid chronotherapy. Therefore, bedtime methotrexate chronotherapy was found to better manage RA symptoms, and several available NSAIDs (i.e. indomethacin, aceclofenac, ketoprofen, flurbiprofen, lornoxicam) have been recently modified in their formulation, in order to obtain more focused night action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.